Browsing by Author "Andrieu, MN"

Now showing 1 - 5 of 5
  • No Thumbnail Available
    Item
  • No Thumbnail Available
    Item
    Paratracheal extramedullary hematopoiesis
    Kurtman, C; Özbilgin, MK; Andrieu, MN; Çelebioglu, B
    Extramedullary hematopoiesis (EMH) is a rare finding in hematology. A 73-year-old female patient with a 1-week history of severe progressive dyspnea was examined, and computed tomography (CT) showed a paratracheal mass 3 cm in size located 1 cm below the vocals cords and causing obliteration of the tracheal airway. Cytology of a needle biopsy revealed EMH. External radiotherapy of 200-cGy fractions to a total dose of 2000 cGy was administered with 3-dimensional conformal planning to treat the progressive symptoms. The patient's clinical symptoms started to improve 2 days after radiotherapy and had completely disappeared after 7 days. CT scans showed complete response on follow-up at 1 week to 5 months after radiotherapy. Mature and immature hematopoietic cells and many adipose cells were seen in the pretreatment samples. Histologic findings in the posttreatment samples showed that these cells had completely disappeared due to the conformal radiotherapy. On the basis of clinical, radiologic, and histologic results, we suggest that conformal radiotherapy may be useful for the treatment of paratracheal localization of EMH because good tumoral irradiation was obtained in this case, with the protection of normal tissues. Int J Hematol. 2001:73:492-495. (C) 2001 The Japanese Society of Hematology.
  • No Thumbnail Available
    Item
    In vivo study to evaluate the protective effects of amifostine on radiation-induced damage of testis tissue
    Andrieu, MN; Kurtmann, C; Hicsonmez, A; Ozbilgin, K; Eser, E; Erdemli, E
    Objective: To investigate the early protective effects of amifostine against radiation-induced damage on rat testis tissue. Methods: Eighty adult male Wistar rats were randomized to 4 groups: Saline solution was given to group A for control, 200 mg/kg amifostine (WR-2721) to group B, a single fraction of 6 Gy local irradiation to testes in group C and 200 mg/kg amifostine 15-30 min before 6 Gy testicular irradiation to group D. Animals were sacrificed 3 weeks after treatment and their testes were removed for macroscopic, microscopic and ultrastructural histopathological examination. Results: The weights, widths and lengths of testes in the last 3 groups had decreased significantly when compared with the control group, but the decrease in widths after irradiation was found to be significantly less only in the amifostine plus radiation group. There was a significant reduction of testis weights in relation to the individual body weights in the irradiated testes compared with the other groups (p < 0.005), while there was no significant change of testis weight/total body weight ratio in amifostine plus irradiation group. Spermatogonium A and primary spermatocyte counts were also less in the treatment groups, and primary spermatocyte numbers were significantly higher in amifostine plus radiation group when compared with radiation alone group (p < 0.005). Pretreatment with amifostine reduced the decrease of primary spermatocyte counts by a factor of 1.28. Electron microscopic analysis did not show any cytotoxic effect of amifostine alone, and furthermore, ultrastructural findings were normal with the addition of amifostine prior to irradiation, though there was damage in the radiation exposure group. Conclusion: Amifostine when given alone by itself appears to cause adverse alterations in testis tissue; however, it has a radioprotective effect on spermiogenetic cells when used prior to radiation. Copyright (C) 2005 S. Karger AG, Basel.
  • No Thumbnail Available
    Item
    Patterns of care for lung cancer in radiation oncology departments of Turkey
    Demiral, A; Alicikus, ZA; Ugur, V; Karadogan, I; Yoney, A; Andrieu, MN; Yalman, D; Pak, Y; Aksu, G; Ozyigit, G; Ozkan, L; Kilciksiz, S; Koca, S; Caloglu, M; Yavuz, A; Caglar, H; Beyzad-eoglu, M; Igdem, S; Serin, M; Kaplan, B; Koc, M; Korkmaz, E; Celik, OK; Kinay, M
  • No Thumbnail Available
    Item
    PATTERNS OF CARE FOR LUNG CANCER IN RADIATION ONCOLOGY DEPARTMENTS OF TURKEY
    Demiral, AN; Alicikus, ZA; Ugur, VI; Karadogan, I; Yöney, A; Andrieu, MN; Yalman, D; Pak, Y; Aksu, G; Özyigit, G; Özkan, L; Kilçiksiz, S; Koca, S; Çaloglu, M; Yavuz, AA; Çaglar, HB; Beyzadeoglu, M; Igdem, S; Serin, M; Kaplan, B; Koç, M; Korkmaz, E; Karakoyun-Çelik, Ö; Dinçer, S; Kinay, M
    Purpose: To determine the patterns of care for lung cancer in Turkish radiation oncology centers. Methods and Materials: Questionnaire forms from 21 of 24 (87.5%) centers that responded were evaluated. Results: The most frequent histology was non-small cell lung cancer (NSCLC) (81%). The most common postoperative radiotherapy (RT) indications were close/(+) surgical margins (95%) and presence of pN2 disease (91%). The most common indications for postoperative chemotherapy (CHT) were >= IB disease (19%) and the presence of pN2 disease (19%). In Stage IIIA potentially resectable NSCLC, the most frequent treatment approach was neoadjuvant concomitant chemoradiotherapy (CHRT) (57%). In Stage IIIA unresectable and Stage IIIB disease, the most frequent approach was definitive concomitant CHRT (91%). In limited SCLC, the most common treatment approach was concomitant CHRT with cisplatin+etoposide for cycles 1-3, completion of CHT to cycles 4-6, and finally prophylactic cranial irradiation in patients with complete response (71%). Six cycles of cisplatin + etoposide CHT and palliative thoracic RT, when required, was the most commonly used treatment (81%) in extensive SCLC. Sixty-two percent of centers did not have endobronchial brachytherapy (EBB) facilities. Conclusion: There is great variation in diagnostic testing, treatment strategies, indications for postoperative RT and CHT, RT features, and EBB availability for LC cases. To establish standards, national guidelines should be prepared using a multidisciplinary approach. (c) 2008 Elsevier Inc.